Antithrombin Enhancement May Improve Anticoagulation Efficiency in Infants Undergoing Cardiopulmonary Bypass for Cardiac Surgery

PHASE3CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Cardiopulmonary Bypass
Interventions
DRUG

Antithrombin III

Patients randomized to receive Antithrombin concentrate will receive a dose of AT to achieve a target value of 1.2U/ml.

OTHER

Saline Placebo

Patients randomized to the control group will receive a placebo consisting of normal saline in a volume equivalent to the volume of antithrombin the same patient in the treatment group would have received and administered by anesthesia and perfusion in the exact same manner as the AT is administered in the treatment group.

Trial Locations (1)

M5V1X8

The Hospital for Sick Children, Toronto

All Listed Sponsors
lead

The Hospital for Sick Children

OTHER

NCT01530737 - Antithrombin Enhancement May Improve Anticoagulation Efficiency in Infants Undergoing Cardiopulmonary Bypass for Cardiac Surgery | Biotech Hunter | Biotech Hunter